Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women (REJOICE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02253173
Recruitment Status : Completed
First Posted : October 1, 2014
Results First Posted : May 25, 2017
Last Update Posted : May 25, 2017
Sponsor:
Information provided by (Responsible Party):
TherapeuticsMD

Tracking Information
First Submitted Date  ICMJE September 26, 2014
First Posted Date  ICMJE October 1, 2014
Results First Submitted Date  ICMJE August 8, 2016
Results First Posted Date  ICMJE May 25, 2017
Last Update Posted Date May 25, 2017
Study Start Date  ICMJE September 2014
Actual Primary Completion Date October 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 20, 2017)
  • Co-Primary Efficacy Endpoint - Vaginal Superficial Cells [ Time Frame: Baseline and 12 Weeks ]
    • Change from Baseline to Week 12 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo
  • Co-Primary Efficacy Endpoint - Vaginal Parabasal Cells [ Time Frame: Baseline and 12 Weeks ]
    • Change from Baseline to Week 12 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo
  • Co-Primary Efficacy Endpoint - Vaginal pH [ Time Frame: Baseline and 12 Weeks ]
    • Change from Baseline to Week 12 in vaginal pH as compared to placebo
  • Co-Primary Efficacy Endpoint - Severity of Most Bothersome Symptom (Dyspareunia) [ Time Frame: Baseline and Week 12 ]
    • Change from Baseline to Week 12 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 12
Original Primary Outcome Measures  ICMJE
 (submitted: September 30, 2014)
  • Co-Primary Efficacy Endpoint - Vaginal Superficial Cells [ Time Frame: 12 Weeks ]
    • Change from Baseline to Week 12 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo
  • Co-Primary Efficacy Endpoint - Vaginal Parabasal Cells [ Time Frame: 12 Weeks ]
    • Change from Baseline to Week 12 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo
  • Co-Primary Efficacy Endpoint - Vaginal pH [ Time Frame: 12 Weeks ]
    • Change from Baseline to Week 12 in vaginal pH as compared to placebo
  • Co-Primary Efficacy Endpoint - Severity of Most Bothersome Symptom (Dyspareunia) [ Time Frame: 12 Weeks ]
    • Change from baseline to week 12 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo
Change History Complete list of historical versions of study NCT02253173 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: April 20, 2017)
  • Secondary Efficacy Endpoints - Vaginal Superficial Cells [ Time Frame: Baseline and Week 2 ]
    • Change from Baseline to Week 2 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo
  • Secondary Efficacy Endpoints- Vaginal Superficial Cells [ Time Frame: Baseline and Week 6 ]
    Change from Baseline to Week 6 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo
  • Secondary Efficacy Endpoints - Vaginal Superficial Cells [ Time Frame: Baseline and Week 8 ]
    Change from Baseline to Week 8 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo
  • Secondary Efficacy Endpoints - Vaginal Parabasal Cells [ Time Frame: Baseline and Week 2 ]
    Change from Baseline to Week 2 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo
  • Secondary Efficacy Endpoints - Vaginal Parabasal Cells [ Time Frame: Baseline and Week 6 ]
    Change from Baseline to Week 6 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo
  • Secondary Efficacy Endpoints - Vaginal Parabasal Cells [ Time Frame: Baseline and Week 8 ]
    Change from Baseline to Week 8 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo
  • Secondary Efficacy Endpoints - Vaginal pH [ Time Frame: Baseline and Week 2 ]
    Change from Baseline to Week 2 in vaginal pH as compared to placebo
  • Secondary Efficacy Endpoints - Vaginal pH [ Time Frame: Baseline and Week 6 ]
    Change from Baseline to Week 6 in vaginal pH as compared to placebo
  • Secondary Efficacy Endpoints - Vaginal pH [ Time Frame: Baseline and Week 8 ]
    Change from Baseline to Week 8 in vaginal pH as compared to placebo
  • Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia) [ Time Frame: Baseline and Week 2 ]
    Change from Baseline to Week 2 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 2
  • Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia) [ Time Frame: Baseline and Week 6 ]
    Change from Baseline to Week 6 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 6
  • Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia) [ Time Frame: Baseline and Week 8 ]
    Change from Baseline to Week 8 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 8
  • Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness) [ Time Frame: Baseline and Week 2 ]
    Change from Baseline to Week 2 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 2
  • Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness) [ Time Frame: Baseline and Week 6 ]
    Change from Baseline to Week 6 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 6
  • Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness) [ Time Frame: Baseline and Week 8 ]
    Change from Baseline to Week 8 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 8
  • Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness) [ Time Frame: Baseline and Week 12 ]
    Change from Baseline to Week 12 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 12
  • Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation) [ Time Frame: Baseline and Week 2 ]
    Change from Baseline to Week 2 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 2
  • Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation) [ Time Frame: Baseline and Week 6 ]
    Change from Baseline to Week 6 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 6
  • Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation) [ Time Frame: Baseline and Week 8 ]
    Change from Baseline to Week 8 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 8
  • Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation) [ Time Frame: Baseline and Week 12 ]
    Change from Baseline to Week 12 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 12
  • Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color) [ Time Frame: Baseline and Week 2 ]
    Change from Baseline to Week 2 in Vaginal Color as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 2
  • Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color) [ Time Frame: Baseline to Week 6 ]
    Change from Baseline to Week 6 in Vaginal Color as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 6
  • Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color) [ Time Frame: Baseline to Week 8 ]
    Change from Baseline to Week 8 in Vaginal Color as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 8
  • Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color) [ Time Frame: Baseline and Week 12 ]
    Change from Baseline to Week 12 in Vaginal Color as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 12
  • Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity) [ Time Frame: Baseline and Week 2 ]
    Change from Baseline to Week 2 in Vaginal Epithelial Integrity as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3 Severity was assessed by the Investigator at Baseline and Week 2
  • Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity) [ Time Frame: Baseline and Week 6 ]
    Change from Baseline to Week 6 in Vaginal Epithelial Integrity as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3 Severity was assessed by the Investigator at Baseline and Week 6
  • Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity) [ Time Frame: Baseline and Week 8 ]
    Change from Baseline to Week 8 in Vaginal Epithelial Integrity as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3 Severity was assessed by the Investigator at Baseline and Week 8
  • Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity) [ Time Frame: Baseline and Week 12 ]
    Change from Baseline to Week 12 in Vaginal Epithelial Integrity as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3 Severity was assessed by the Investigator at Baseline and Week 12
  • Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness) [ Time Frame: Baseline and Week 2 ]
    Change from Baseline to Week 2 in Vaginal Epithelial Surface Thickness as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe [smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)] = 3 Severity was assessed by the Investigator at Baseline and Week 2
  • Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness) [ Time Frame: Baseline and Week 6 ]
    Change from Baseline to Week 6 in Vaginal Epithelial Surface Thickness as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe [smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)] = 3 Severity was assessed by the Investigator at Baseline and Week 6
  • Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness) [ Time Frame: Baseline and Week 8 ]
    Change from Baseline to Week 8 in Vaginal Epithelial Surface Thickness as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe [smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)] = 3 Severity was assessed by the Investigator at Baseline and Week 8
  • Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness) [ Time Frame: Baseline and Week 12 ]
    Change from Baseline to Week 12 in Vaginal Epithelial Surface Thickness as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe [smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)] = 3 Severity was assessed by the Investigator at Baseline and Week 12
  • Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions) [ Time Frame: Baseline and Week 2 ]
    Change from Baseline to Week 2 in Vaginal Secretions as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain) = 3 Severity was assessed by the Investigator at Baseline and Week 2
  • Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions) [ Time Frame: Baseline and Week 6 ]
    Change from Baseline to Week 6 in Vaginal Secretions as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain] = 3 Severity was assessed by the Investigator at Baseline and Week 6
  • Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions) [ Time Frame: Baseline and Week 8 ]
    Change from Baseline to Week 8 in Vaginal Secretions as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain] = 3 Severity was assessed by the Investigator at Baseline and Week 8
  • Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions) [ Time Frame: Baseline and Week 12 ]
    Change from Baseline to Week 12 in Vaginal Secretions as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain] = 3 Severity was assessed by the Investigator at Baseline and Week 12
  • Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) - Total Score [ Time Frame: Baseline and Week 12 ]
    Change from Baseline to Week 12 in FSFI Total Score as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
  • Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Arousal [ Time Frame: Baseline and Week 12 ]
    Change from Baseline to Week 12 in FSFI Domain Score (Arousal) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
  • Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Desire [ Time Frame: Baseline and Week 12 ]
    Change from Baseline to Week 12 in FSFI Domain Score (Desire) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
  • Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Lubrication [ Time Frame: Baseline and Week 12 ]
    Change from Baseline to Week 12 in FSFI Domain Score (Lubrication) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
  • Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Orgasm [ Time Frame: Baseline and Week 12 ]
    Change from Baseline to Week 12 in FSFI Domain Score (Orgasm) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
  • Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Pain [ Time Frame: Baseline and Week 12 ]
    Change from Baseline to Week 12 in FSFI Domain Score (Pain) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
  • Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Satisfaction [ Time Frame: Baseline and Week 12 ]
    Change from Baseline to Week 12 in FSFI Domain Score (Satisfaction) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
Original Secondary Outcome Measures  ICMJE
 (submitted: September 30, 2014)
  • Secondary Efficacy Endpoints - Vaginal Superficial and Parabasal Cells, Vaginal pH and Severity of MBS (dyspareunia) [ Time Frame: 2, 6 and 8 Weeks ]
    • Change from baseline to weeks 2, 6, and 8 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo
    • Change from baseline to weeks 2, 6 and 8 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo
    • Change from baseline to weeks 2, 6 and 8 in vaginal pH as compared to placebo
    • Change from baseline to weeks 2, 6 and 8 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo
  • Secondary Efficacy Endpoints - Severity of other VVA symptoms and visual evaluation of vaginal mucosa [ Time Frame: 2, 6, 8 and 12 Weeks ]
    • Change from baseline to weeks 2, 6, 8 and 12 on the severity of the vaginal dryness and vaginal and/or vulvar itching or burning associated with VVA as compared to placebo
    • Change in visual evaluation of the vaginal mucosa from baseline to weeks 2, 6, 8 and 12 compared to placebo
  • Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) [ Time Frame: 12 Weeks ]
    • Change from baseline in the FSFI at week 12 compared to placebo
  • Secondary Efficacy Endpoints - Hormone Concentration Assessments (serum estradiol, estrone and estrone conjugates; SHBG) - PK Substudy [ Time Frame: Pre-treatment, Day 1, Weeks 2 and 12 ]
    Blood samples will be obtained from a subset of subjects at pre-selected sites to characterize PK parameters (AUC, tmax, Cmin, Cmax) and to measure SHBG
Current Other Pre-specified Outcome Measures
 (submitted: April 20, 2017)
PK Substudy - Hormone Concentration Assessments (Serum Estradiol, Estrone and Estrone Conjugates; SHBG) [ Time Frame: Pre-treatment, Day 2, Weeks 2 and 12 ]
Blood samples will be obtained from a subset of subjects at pre-selected sites to characterize PK parameters (AUC, tmax, Cmin, Cmax, Cavg) and to measure SHBG
Original Other Pre-specified Outcome Measures
 (submitted: September 30, 2014)
Safety Endpoints - Adverse Events, Vital Signs, Physical Exam Findings, Gynecological Exam Findings, Clinical Lab Tests, Endometrial Biopsies [ Time Frame: 12 Weeks ]
Adverse events and serious adverse events (SAEs) will be summarized for each treatment group and overall for all active treatment groups with the proportion of subjects reporting each event. Actual values and change from baseline in vital signs, and all laboratory test parameters will be summarized for each treatment group and overall for all active treatment groups with descriptive statistics at each assessment obtained. The incidence rate for endometrial hyperplasia will be calculated for each treatment group.
 
Descriptive Information
Brief Title  ICMJE Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women
Official Title  ICMJE A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate the Safety and Efficacy of TX-004HR in Postmenopausal Women With Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy
Brief Summary This study will assess the safety and efficacy of a new formulation of vaginal estradiol for the treatment of symptoms of vulvar and vaginal atrophy in postmenopausal women.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE
  • Vulvovaginal Atrophy
  • Menopause
  • Dyspareunia
  • Painful Intercourse
Intervention  ICMJE
  • Drug: Estradiol
  • Drug: Placebo
Study Arms  ICMJE
  • Experimental: Estradiol 4mcg Vaginal Softgel Capsule
    Estradiol 4mcg Vaginal Softgel Capsule
    Intervention: Drug: Estradiol
  • Experimental: Estradiol 10mcg Vaginal Softgel Capsule
    Estradiol 10mcg Vaginal Softgel Capsule
    Intervention: Drug: Estradiol
  • Experimental: Estradiol 25mcg Vaginal Softgel Capsule
    Estradiol 25mcg Vaginal Softgel Capsule
    Intervention: Drug: Estradiol
  • Placebo Comparator: Placebo Vaginal Softgel Capsule
    Placebo Vaginal Softgel Capsule
    Intervention: Drug: Placebo
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: November 2, 2015)
764
Original Estimated Enrollment  ICMJE
 (submitted: September 30, 2014)
700
Actual Study Completion Date  ICMJE October 2015
Actual Primary Completion Date October 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Postmenopausal female subjects between the ages of 40 and 75 years (at the time of randomization) with at least:

    • 12 months of spontaneous amenorrhea (women <55 years of age with a history of hysterectomy without bilateral oophorectomy prior to natural menopause must have follicle stimulating hormone (FSH) levels > 40 mIU/mL), OR
    • 6 months of spontaneous amenorrhea with follicle stimulating hormone (FSH) levels > 40mlU/mL OR
    • At least 6 weeks postsurgical bilateral oophorectomy.
  2. ≤5% superficial cells on vaginal cytological smear
  3. Vaginal pH > 5.0
  4. Moderate to severe symptom of vaginal pain associated with sexual activity considered the most bothersome vaginal symptom by the subject at screening visit 1A.
  5. Moderate to severe symptom of vaginal pain associated with sexual activity at screening visit 1B.
  6. Onset of moderate to severe dyspareunia in the postmenopausal years.
  7. Subjects should be sexually active (i.e. have sexual activity with vaginal penetration within approximately 1 month of screening visit 1A).
  8. Subjects should anticipate having sexual activity (with vaginal penetration) during the conduct of the trial.
  9. For subjects with an intact uterus: Subjects must have an acceptable result from an evaluable screening endometrial biopsy.
  10. Subjects who have a Body Mass Index (BMI) less than or equal to 38 kg/m2. BMI values should be rounded to the nearest integer (ex. 32.4 rounds down to 32, while 26.5 rounds up to 27).
  11. In the opinion of the investigator, the subject will comply with the protocol and has a high probability of completing the study.

Exclusion Criteria:

  1. Use of the following:

    1. Oral estrogen-, progestin-, androgen-, or SERM-containing drug products within 8 weeks before screening visit 1A (can enter washout);
    2. Use of transdermal hormone products within 4 weeks before screening visit 1A (can enter washout);
    3. Use of vaginal hormone products (rings, creams, gels) within 4 weeks before screening visit1A (can enter washout);
    4. Use of intrauterine progestins within 8 weeks before screening visit 1A (can enter washout);
    5. Use of progestin implants/injectables or estrogen pellets/injectables within 6 months before screening visit 1A (cannot enter washout);
    6. Use of vaginal lubricants or moisturizers within 7 days before the screening visit 1B vaginal pH assessment.
  2. A history or active presence of clinically important medical disease that might confound the study or be detrimental to the subject, examples include:

    1. Hypersensitivity to estrogens;
    2. Endometrial hyperplasia;
    3. Undiagnosed vaginal bleeding;
    4. Have a history of a chronic liver or kidney dysfunction/disorder (e.g., Hepatitis C or chronic renal failure);
    5. Thrombophlebitis, thrombosis or thromboembolic disorders;
    6. Cerebrovascular accident, stroke, or transient ischemic attack;
    7. Myocardial infarction or ischemic heart disease;
    8. Malignancy or treatment for malignancy, within the previous 5 years, with the exception of basal cell carcinoma of the skin or squamous cell carcinoma of the skin. A history of estrogen dependent neoplasia, breast cancer, melanoma or any gynecologic cancer, at any time, excludes the subject;
    9. Endocrine disease (except for controlled hypothyroidism or controlled non-insulin dependent diabetes mellitus).
  3. Recent history of known alcohol or drug abuse.
  4. History of sexual abuse or spousal abuse that, in the opinion of the PI, may interfere with the subject's assessment of vaginal pain with sexual activity.
  5. Current history of Heavy smoking (more than 15 cigarettes per day) or use of e-cigarettes.
  6. Use of an intrauterine device within 12 weeks before screening visit 1A.
  7. Use of an investigational drug within 60 days before screening visit 1A.
  8. Any clinically important abnormalities on screening physical exam, assessments, ECG, or laboratory tests, such as:

    1. Unresolved cervical cytologic smear report of atypical glandular cells of undetermined significance (AGUS) or atypical squamous cells of undetermined significance (ASCUS).

      Cervical cytologic smear report of low-grade squamous intraepithelial lesion (SIL) or greater, CIN1 or greater, or any reported dysplasia; Subjects with ASCUS are eligible only if high risk human papilloma virus (HPV) result is negative.

    2. Unresolved findings suspicious for malignancy on the breast exam; incomplete mammogram result (BI-RADS 0) or unresolved findings suggestive of malignant changes or findings requiring short interval follow-up on the prestudy mammogram (subjects must have mammography result of BI-RADS 1 or 2 to enroll.) Mammogram may be performed within 9 months prior to Visit 2 (randomization) with documentation available. (The site must obtain a copy of the official report for the subject's study file, and it must be verified that the mammogram itself is available if needed for additional assessment);
    3. In subjects with intact uterus: have a screening endometrial biopsy sample that is found by both primary pathologists to have endometrial tissue insufficient for diagnosis, no endometrium identified, or no tissue identified. (With the approval of the Medical Monitor, the screening endometrial biopsy may be repeated once);
    4. In subjects with intact uterus: an endometrial biopsy report by one central pathologist at screening with one of the following:

      • Endometrial hyperplasia endometrial cancer, proliferative endometrium, weakly proliferative endometrium, disordered proliferative pattern; OR
      • Endometrial polyps with hyperplasia, glandular atypia of any degree (e.g., atypical nuclei) or cancer;
    5. Vulvar or vaginal inflammatory condition such as a contact or allergic dermatitis, lichen sclerosis or other pathological findings;
    6. Presence of suspicious vulvar or vaginal lesions for dysplasia, malignancy or other pathology other than atrophy;
    7. Painful genital warts or localized areas of ulceration;
    8. A history of active, chronic pelvic pain;
    9. Interstitial cystitis;
    10. Serum alanine aminotransferase (ALT) or serum aspartate aminotransferase (AST) greater than 1.5 times the upper limit of normal for the laboratory used;
    11. Fasting total cholesterol greater than 300 mg/dL (7.77 mmol/L) or triglycerides greater than 300 mg/dL (3.39 mmol/L);
    12. Fasting blood glucose greater than 125 mg/dL (6.94 mmol/L) with a hemoglobin A1C of greater than or equal to 6.5%;
    13. Uncontrolled hypertension; subjects with elevated sitting blood pressure, greater than 140 mm Hg systolic or greater than 90 mm Hg diastolic and may not be using more than 2 antihypertensive medications for the treatment of hypertension;
    14. Clinically significant abnormal 12-lead ECG (such as myocardial infarction or other findings suggestive of ischemia)
  9. Be known to be pregnant or have a positive urine pregnancy test. (Note: A pregnancy test is not required for subjects who have had bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or are 55 years old or greater and have experienced cessation of menses for at least 1 year.
  10. Current use of marijuana.
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 40 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02253173
Other Study ID Numbers  ICMJE TXV14-01
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party TherapeuticsMD
Study Sponsor  ICMJE TherapeuticsMD
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account TherapeuticsMD
Verification Date April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP